Compare CHH & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHH | PTCT |
|---|---|---|
| Founded | 1939 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.7B |
| IPO Year | 1997 | 2006 |
| Metric | CHH | PTCT |
|---|---|---|
| Price | $115.01 | $78.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 17 |
| Target Price | ★ $114.30 | $80.65 |
| AVG Volume (30 Days) | 626.2K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | 27.42 | ★ 264.48 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $1,596,793,000.00 | $264,734,000.00 |
| Revenue This Year | $66.74 | N/A |
| Revenue Next Year | $0.37 | $17.70 |
| P/E Ratio | $261.02 | ★ N/A |
| Revenue Growth | 0.75 | ★ 36.19 |
| 52 Week Low | $84.04 | $43.18 |
| 52 Week High | $136.45 | $87.50 |
| Indicator | CHH | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 63.72 |
| Support Level | $102.06 | $73.41 |
| Resistance Level | $116.89 | $79.67 |
| Average True Range (ATR) | 4.30 | 3.08 |
| MACD | 0.70 | 0.69 |
| Stochastic Oscillator | 80.87 | 91.83 |
At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2025.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.